Molecular Longitudinal Tracking of Mycobacterium abscessus spp. during Chronic Infection of the Human Lung

Citation for published version:
Kreutzfeldt, KM, McAdam, PR, Claxton, P, Holmes, A, Seagar, AL, Laurenson, IF & Fitzgerald, JR 2013, 'Molecular Longitudinal Tracking of Mycobacterium abscessus spp. during Chronic Infection of the Human Lung' PLoS One, vol 8, no. 5, pp. e63237. DOI: 10.1371/journal.pone.0063237

Digital Object Identifier (DOI):
10.1371/journal.pone.0063237

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
PLoS One

Publisher Rights Statement:
Copyright: © 2013 Kreutzfeldt et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Molecular Longitudinal Tracking of *Mycobacterium abscessus* spp. during Chronic Infection of the Human Lung

Kaj M. Kreutzfeldt¹, Paul R. McAdam¹, Pauline Claxton², Anne Holmes¹, A. Louise Seagar², Ian F. Laurenson², J. Ross Fitzgerald¹*

¹ The Roslin Institute and Edinburgh Infectious Diseases, University of Edinburgh, Easter Bush Campus, Edinburgh, United Kingdom. ² Scottish Mycobacteria Reference Laboratory (SMRL), Clinical Microbiology, Royal Infirmary of Edinburgh, Little France, Edinburgh, United Kingdom

Abstract

The *Mycobacterium abscessus* complex is an emerging cause of chronic pulmonary infection in patients with underlying lung disease. The *M. abscessus* complex is regarded as an environmental pathogen but its molecular adaptation to the human lung during long-term infection is poorly understood. Here we carried out a longitudinal molecular epidemiological analysis of 178 *M. abscessus* spp. isolates obtained from 10 cystic fibrosis (CF) and 2 non CF patients over a 13 year period. Multi-locus sequence and molecular typing analysis revealed that 11 of 12 patients were persistently colonized with the same genotype during the course of the infection while replacement of a *M. abscessus sensu stricto* strain with a *Mycobacterium massiliense* strain was observed for a single patient. Of note, several patients including a pair of siblings were colonized with closely-related strains consistent with intra-familial transmission or a common infection reservoir. In general, a switch from smooth to rough colony morphology was observed during the course of long-term infection, which in some cases correlated with an increasing severity of clinical symptoms. To examine evolution during long-term infection of the CF lung we compared the genome sequences of 6 sequential isolates of *Mycobacterium bolletii* obtained from a single patient over an 11 year period, revealing a heterogeneous clonal infecting population with mutations in regulators controlling the expression of virulence factors and complex lipids. Taken together, these data provide new insights into the epidemiology of *M. abscessus* spp. during long-term infection of the CF lung, and the molecular transition from saprophytic organism to human pathogen.

Introduction

The *Mycobacterium abscessus* complex is a group of rapidly growing mycobacteria (RGM) that is associated with an array of human infections typically affecting the lungs, skin or soft tissues [1–4]. Chronic lung infection is most frequently observed in patients with underlying lung disease, especially those suffering from cystic fibrosis (CF) [5,6], and *M. abscessus* spp. infections in CF patients are linked to disease progression [2]. *M. abscessus* complex is subdivided into the 3 species *M. abscessus sensustricto*, *Mycobacterium massiliense* and *Mycobacterium bolletii* which exhibit clinically relevant differences in antibiotic sensitivity profile [7–9].

Chronic infections caused by environmental pathogens are characterized by the ability of the infecting organisms to adapt to a very different niche habitat, leading to changes in phenotype influencing colony morphology, inflammatory response, and antibiotic resistance [10–12]. Like other RGM the *M. abscessus* spp. are saprophytic organisms associated with water reservoirs linked to human activity [13,14]. *M. abscessus sensu stricto* is innately resistant to many classes of antibiotic [15] and readily acquires resistance to clarithromycin during infection [16]. In addition, *M. abscessus sensu stricto* exhibits differences in colony morphology including smooth colony variants typical of environmental and early infection isolates [6] which are replaced over a period of years with rough variants capable of invasion of macrophage and respiratory epithelial cells, and associated with severe inflammation [17,18]. Previous studies have demonstrated the long-term persistence of single *M. abscessus* spp. strains during chronic infection of the CF lung with occasional sharing of strains between sibling pairs, implying that transmission between patients may occur [19]. A recent study provided evidence for an outbreak involving *M. massiliense* infection of 5 patients attending a CF clinic implying that some strains of *M. abscessus* complex may have epidemic potential [1].

The phenomenon of long-term persistence of *M. abscessus* complex during chronic infection of the human lung is well established. However, the relative prevalence of the 3 *M. abscessus* species among long-term infected patients, and the capacity of *M. abscessus* complex to transmit between patients have not been well examined. Here, we carry out longitudinal molecular tracking of
| Patient 1  | Patient 2  | Patient 3  | Patient 4  | Patient 5  | Patient 6  |
|-----------|------------|------------|------------|------------|------------|
| Year of birth | 1986 | 1985 | 1986 | 1934 | 1960 | 1980 |
| Sex | F | F | F | M | M | F |
| CF status | CF | CF | CF | Non-CF | Non-CF | CF |
| Number of isolates | 25 | 23 | 19 | 18 | 14 | 15 |
| Age in years at first/most recent isolation | 13/25 | 15/21 | 12/24 | 71/76 | 43/46 | 17/19 |
| Species | *M. bolletii* | *M. massiliense* | *M. abscessus sensu stricto* | *M. abscessus sensu stricto* | *M. abscessus sensu stricto* | *M. massiliense* |
| Sequence type | 119 | 23 | 26 | 120 | 121 | 23 |
| ERIC-PCR type | 12 | 3 | 8 | 9 | 10 | 4 |
| Colony morphology | | | | | | |
| Smooth to rough switch | x | x | x | | | |
| Rough only | | | | x | x | |
| Mixed smooth and rough | x | | | x | | |
| Clinical comments | See text | Died aged 21 y | Alive | Acute myeloid leukaemia, COPD, died aged 77 y | Alcoholic liver disease with liver cirrhosis, bronchiectasis, died aged 48 y | Died aged 21 y |

| Patient 7  | Patient 8  | Patient 9  | Patient 10 | Patient 11 | Patient 12 |
|-----------|------------|------------|------------|------------|------------|
| Year of birth | 1975 | 1989 | 1992 | 1983 | 1988 | 1987 |
| Sex | M | M | F | F | F | F |
| CF status | CF | CF | CF | CF | CF | CF |
| Number of isolates | 15 | 12 | 12 | 10 | 9 | 6 |
| Age in years at first/most recent isolation | 23/29 | 10/16 | 12/14 | 19/25 | 16/21 | 13/15 |
| Species | *M. massiliense* | *M. massiliense* | *M. abscessus sensu stricto* | *M. abscessus sensu stricto* | *M. bolletii* | *M. massiliense* |
| Sequence type | 69 | 23 | 122/23 | 123 | 124 | 23 |
| ERIC-PCR type | 5 | 4 | 7/2 | 6 | 11 | 1 |
| Colony morphology | | | | | | |
| Smooth to rough switch | x | x | x | | | |
| Rough only | x | x | x | | | |
| Mixed smooth and rough | | | | | | |
| Clinical comments | Died aged 32 y | Died aged 21 y | Died aged 14 y | Alive | Died aged 21 y | Cleared infection, lung transplant aged 17 y |
M. abscessus complex isolates from chronically infected patients with multi-locus sequence and PCR-based bacterial typing. We also combine whole genome sequencing of sequential isolates with phenotypic analysis of colony morphology and antibiotic sensitivity to examine the adaptive diversification of M. abscessus spp. during chronic infection of the human lung revealing a genetically and phenotypically heterogeneous infecting population. In addition, the data provide molecular correlates of adaptation of M. abscessus spp. to the human lung that will inform future studies investigating M. abscessus pathogenesis.

Materials and Methods

M. abscessus Complex Isolates and Culture Conditions
All clinical isolates were referred to the Scottish Mycobacteria Reference Laboratory (SMRL) for identification, susceptibility testing, DNA extraction and long-term storage. Ethical approval for use of samples/data was provided by the National Health Service, South East of Scotland HSS BioResource facility operating within the Tissue Act Scotland 2006. The Scientific Officer indicated that the research does not need NHS ethical review under the terms of the Governance Arrangements for Research Ethics Committees (A Harmonised Edition). In particular, research limited to secondary use of information previously collected in the course of normal care (without an intention to use it for research at the time of collection) is generally excluded from REC review, provided that the patients or service users are not identifiable to the research team carrying out the research. The review board waived the need for written informed consent from the participants.

A total of 178 M. abscessus spp. pulmonary isolates were obtained from 12 patients in Scotland between 1998 and 2010, including 10 unrelated patients and 1 sibling pair. Annual incidence of M. abscessus spp. infection is estimated at ~887/100,000 in Scottish cystic fibrosis patients or about 8 patients annually (Scottish Mycobacterium Reference laboratory, data not shown). Of the 12 patients, 10 suffered from cystic fibrosis and 2 had significant co-morbidities including cirrhotic alcoholic liver disease, and acute myeloid leukemia, both with chronic pulmonary disease (Table 1). The mean age at first isolation of M. abscessus amongst the CF patients was 13 y (range 12–23 y). One CF patient successfully cleared carriage and went on to lung transplantation. Isolates were identified as M. abscessus spp. by GenoType Mycobacterium CM test (HAIN Lifescience, Germany). Species type strains included M. abscessus NCTC 13031, M. bolletii DSM 45149 and M. massiliense DSM 45103. Isolates were cultured on Loewenstein Jensen egg slopes or Columbia Horse Blood Agar (Oxoid, Hampshire, UK) statically at 37°C.

Genomic DNA Extraction
Genomic DNA (gDNA) was extracted from bacteria following the method described by van Soolingen et al. [20] and previously used for M. abscessus spp. [21]. DNA yield was quantified using a Nanodrop ND-1000 Spectrophotometer (Thermo Scientific, USA).

ERIC-PCR Typing
For ERIC-PCR, 50 μl reactions included 2 μM forward and reverse oligonucleotide primers described by Sechi et al. [22], 0.25 U of Go-Taq Flexi DNA Polymerase, 5x Green Go Taq Flexi Buffer, 1.5 mM MgCl₂, 200 μM dNTPs (Promega, Hampshire, UK) and 10 ng approx. gDNA. Thermocycling conditions were 3 min at 95°C followed by 30 cycles of 95°C for 1 min, 55°C for 1 min and 72°C for 5 min with a final extension of 10 min at 72°C. Agarose gel electrophoresis of ERIC-PCR products was followed by comparative analysis of resolved profiles with the BioNumerics program v5 with clustering by UPGMA with Dice similarity. Independent genomic DNA extractions resulted in indistinguishable ERIC-PCR profiles, demonstrating the method to be highly reproducible (data not shown).

Figure 1. Genotypic analysis of M. abscessus spp. isolates from persistently infected patients. Dendrogram constructed using BioNumerics showing the genetic relatedness among ERIC-PCR profiles of 1 representative isolates from each of the 12 patients. doi:10.1371/journal.pone.0063237.g001
Multi-locus Sequence Typing (MLST)

MLST was carried out as described previously [9]. Briefly, 50 μl PCR reactions specific for the 7 housekeeping loci included 0.2 μM forward and reverse oligonucleotide primers, 0.25 U of Go-Taq Flexi DNA Polymerase, 5x Green Go Taq Flexi Buffer, 1.5 mM MgCl₂, 200 μM dNTPs (Promega, Hampshire, UK) and 10 ng approx. gDNA. Thermocycling conditions were 3 min at 95 °C followed by 30 cycles of 95 °C for 1 min, 55–60 °C for 1 min and 72 °C for 1 min with a final extension of 10 min at 72 °C. Sequencing was carried out by The GenePool Sequencing Service (King’s Buildings, University of Edinburgh, UK), and sequences assembled using Geneious 5.4.2 [23]. Alleles and sequence types were determined using the Institute Pasteur M. abscessus MLST database (http://www.pasteur.fr/recherche/genopole/PF8/mlst/references_abscessus.html). Single and multi-locus phylogenies were re-constructed using a neighbor-joining method with the HKY model of nucleotide substitution, with support for nodes assessed by 1000 bootstrap replicates.

Whole Genome Sequencing and Analysis

Whole genome sequencing was carried out with the Illumina GA2 sequencing platform. The FASTX toolkit [24] was used to assess read quality, remove adaptor sequences, remove 3 bp from the 5’ end of the read and filter reads so that at least 80% of bases within a read were of PHRED score Q30 or above. Paired-end reads were mapped to a draft genome sequence of M. bolletii [25] using the BWA short read aligner [26]. Polymorphic sites were identified at loci covered by at least 3 reads where the alternative base was present in at least two thirds of the reads with PHRED equivalent score greater than 30, and inspected manually. As an additional confirmation, reads were mapped to the genome of M. abscessus sensu stricto strain ATCC 19977 (accession number CU458896), and only those variants present in both reference genomes are reported. A neighbor-joining phylogeny was reconstructed based on the polymorphic sites identified using the HKY substitution model. 1000 bootstrap replicates were used to determine support for key nodes.

Antibiotic Susceptibility Testing

MICs of amikacin, amoxicillin/clavulanic acid, cefepime, cefotaxin, ceftriaxone, ciprofloxacin, clarithromycin, doxycycline, imipenem, linezolid, minocycline, moxifloxacin, tigecycline, tobramycin, trimethoprim/sulphamethoxazole were determined by the Clinical and Laboratory Standards Institute recommended micro-dilution method in Mueller-Hinton broth using Sensititre RGMYCO plates (TREK Diagnostics, USA). Plates were incubated at 37 °C and successive readings were taken after 5, 6, 8, 9, 12 and 14 d of incubation.
Results and Discussion

Molecular Population Genetic Analysis of *M. abscessus* spp. from Chronically Infected Patients

In order to examine the long-term persistence of *M. abscessus* spp. during infection of the human lung, we analyzed a total of 178 sequential *M. abscessus* complex isolates from 12 patients and carried out multi-locus sequence type (MLST) analysis of each unique ERIC-PCR genotype identified in each patient. ERIC-PCR has been shown to be highly discriminatory for grouping outbreak strains of *M. abscessus* spp. and does not suffer from problems of degradation that occur with some electrophoresis-based methods [21]. In total, 12 genotypes representing 9 distinct sequence types (ST), including 6 novel STs and 3 *M. abscessus* complex species, were identified among the 12 patients (Fig. 1; Table 1). For 11 of 12 patients, a single genotype was identified during long-term infection (2 to 12 years) consistent with persistent...
Infection with the same strain. In contrast, for patient 9, the first 5 chronological isolates exhibited a genotype that was distinct from that of the subsequent seven isolates suggesting replacement of the original infecting strain during the course of infection (Fig. 1).

Table 3. Genome variation among sequential M. bolletii isolates from a single patient.

| Gene Product                               | ED1-1 | ED1-2 | ED1-3R | ED1-3S | ED1-4R | ED1-4S |
|--------------------------------------------|-------|-------|--------|--------|--------|--------|
| Arabinosyltransferase C                    |       |       | NS     | NS     | NS     | NS     |
| Prephenate dehydrogenase                   |       |       | NS     | NS     | NS     | NS     |
| Amine oxidase                              |       |       | NS     | NS     | NS     | NS     |
| Glutamate-cysteine ligase GshA             |       |       | NS     | NS     | NS     | NS     |
| Sensor histidine kinase PhoR               |       |       | NS     | NS     | NS     | NS     |
| Putative YrbE family protein               |       |       | NS     | NS     | NS     | NS     |
| Fatty-acid-CoA ligase FadD                 |       |       | NS     | NS     | NS     | NS     |
| Putative alkanesulfonate monoxygenase      | STOP  | STOP  |        |        |        |        |
| Oxidoreductase                             | S     |       |        |        |        |        |
| Indole-3-glycerol-phosphate synthase       |       |       |        |        |        |        |
| Acetolactate synthase                      | NS    |       |        |        |        |        |
| 50S ribosomal protein L14                  | NS    |       |        |        |        |        |
| Ribonuclease III                           | NS    | NS    |        |        |        |        |
| Cytochrome P450                             | NS    |       |        |        |        |        |
| Glycosyltransferase GtfA                   |       |       |        |        |        |        |

| Type of mutation in isolates:              |       |       |        |        |        |        |
| Gene Product                               | ED1-1 | ED1-2 | ED1-3R | ED1-3S | ED1-4R | ED1-4S |
| Hydrogen peroxide-inducible activator      | NS    | NS    |        |        |        |        |
| Putative monoxygenase                      | NS    |       |        |        |        |        |
| Luciferase-like monoxygenase               | S     |       |        |        |        |        |
| Oxalate decarboxylase                      | NS    |       |        |        |        |        |
| PPE family protein                         | NS    | NS    |        |        |        |        |
| 23S ribosomal RNA                          | NS    |       |        |        |        |        |
| Transcriptional regulatory protein         | NS    |       |        |        |        |        |
| Transcriptional regulatory protein         | S     | S     | S      | S      | S      | S      |
| Hypothetical protein                       | NS    |       |        |        |        |        |
| Hypothetical protein                       | STOP  |       |        |        |        |        |
| Hypothetical protein                       | S     |       |        |        |        |        |
| Intergenic Intergenic                     | NCS   | NCS   | NCS    | NCS    | NCS    | NCS    |
| Intergenic Intergenic                     | NCS   | NCS   | NCS    | NCS    | NCS    | NCS    |
| Intergenic Intergenic                     | NCS   | NCS   | NCS    | NCS    | NCS    | NCS    |
| Intergenic Intergenic                     | NCS   | NCS   | NCS    | NCS    | NCS    | NCS    |
| Intergenic Intergenic                     | NCS   | NCS   | NCS    | NCS    | NCS    | NCS    |
| Intergenic Intergenic                     | NCS   | NCS   | NCS    | NCS    | NCS    | NCS    |
| Intergenic Intergenic                     | NCS   | NCS   | NCS    | NCS    | NCS    | NCS    |
| Intergenic Intergenic                     | NCS   | NCS   | NCS    | NCS    | NCS    | NCS    |

*NS, non-synonymous SNP; S, synonymous SNP; NCS, non-coding SNP; FSI, frameshift insertion; FSD, frameshift deletion; NCI, non-coding insertion.
doi:10.1371/journal.pone.0063237.t003
MLST analysis of the isolates from patient 9 revealed that an M. abscessus sensu stricto strain was replaced by an M. massiliense strain (Table 1). Our findings are in agreement with other studies that compared sequential M. abscessus isolates from CF patients highlighting the long-term persistence of M. abscessus, and its treatment-refractory nature [6,27,28]. However, the data indicate for the first time that replacement of M. abscessus by unrelated strains may occur during chronic infection.

M. massiliense ST23 is Prevalent among CF Patients

Single gene trees based on argH, glpK, gsd or murC sequences exhibited 3 distinct clades that co-segregate with the type strains M. abscessus NCTC 13031, M. massiliense DSM 45105 and M. bolletii DSM 45149 (Fig. S1 in File S1). In contrast, the trees constructed with cya, pta and parH sequences have topologies that imply horizontal transfer of these alleles among the M. abscessus complex. Of note, substantial horizontal gene transfer between members of the M. abscessus complex has previously been demonstrated [9]. Phylogenetic reconstruction based on the concatenated sequences of the 4 MLST loci that did not display evidence of horizontal transfer resulted in a tree with 3 well-supported clades, each including one of the M. abscessus species type strains (Fig. 2), facilitating species designation for the clinical isolates. Of the 12 patients, 4 were infected with M. abscessus sensu stricto, 5 with M. massiliense, 2 with M. bolletii and 1 (patient 9) was infected with M. abscessus sensu stricto initially followed by replacement with M. massiliense (Fig. 2; Table 1). Although a number of studies have reported a higher prevalence of M. abscessus sensu stricto among clinical isolates [8,29], Zelaszny et al. reported that M. massiliense was most frequently isolated from the airways of young patients with an underlying lung disease [30]. Notably, 5 of 6 M. massiliense isolates belonged to ST23 which is highly prevalent in the M. abscessus MLST database and has been reported in France, Germany, Switzerland and an outbreak of skin and soft tissue infections in Brazil. The finding that a single sequence type is associated with disease in distant countries is noteworthy and could indicate limited clonal variation among M. massiliense strains. Alternatively, ST23 may represent a M. massiliense subtype with enhanced pathogenic potential, or the capacity to resist aggressive antibiotic treatment.

In the current study, isolates (ED2 and ED12) obtained from a pair of siblings had closely-related genotypes of the same ST23, consistent with a common infective source or cross infection (Fig. 1). Of note, a recent study reports the likely transmission of M. abscessus spp. between patients [1]. Furthermore, M. abscessus spp. have been reported to occur in hospital water distribution systems and clusters of infections have previously been linked to contaminated bronchoscopes [31,32]. Huang et al. typed M. abscessus spp. isolates from clinical and environmental sources linking some infections to M. abscessus spp. present in water distribution systems but the possibility of patient-to-patient transmission could not be excluded [33].

Transition from Smooth to Rough Colony Morphology during Chronic M. abscessus spp. Infection

Previous studies have reported a correlation between a switch in smooth to rough colony morphology and an increase in virulence [34]. In order to determine if M. abscessus spp. undergo changes in colony morphology during long-term infection, the colony phenotype of all isolates was examined. In 5 patients, the majority of earlier isolates in these patients had a smooth colony morphology with a small number of isolates demonstrating a rough colony phenotype. However, over several years of persistent infection, there was an increase in the proportion of isolates with a rough colony morphology leading to uniformly rough colony morphology for the later stage isolates (Table 1, Table S2 from File S2). From patient 1, persistently infected with M. bolletii, 21 of 25 isolates obtained between 1998 and 2005 demonstrated raised, moist, smooth colonies. The remaining four isolates, all collected between 2006 and 2009, contained a mixture of smooth and rough colonies. The timing of the emergence of rough colony phenotype isolates from patient 1 correlates with an increase in severity of clinical disease that was observed in 2005. The transition in colony phenotype has been linked to an increase in severity of infection as the rough phenotype induces an elevated inflammatory response in the host [34]. It is feasible that in the patients with rough colony isolates only, the M. abscessus infection was asymptomatic until a smooth to rough colony phenotype switch resulted in elevated inflammation and clinical symptoms.

Susceptibility of M. bolletii to Antibiotics during Long-term Infection of a Single Patient

In order to examine the antibiotic sensitivity of M. abscessus spp. isolates during long term infection of the CF lung in a patient undergoing defined antibiotic treatment regimens, we examined 6 M. bolletii isolates obtained sequentially from a single patient (Patient 1) over a 12 year period. She had received multiple courses of antimicrobials over 12 years following deterioration in her pulmonary function including a combination of ethambutol, rifampicin and clarithromycin, and had previously been treated with amikacin (Fig. 5). The patient was turned down for lung transplantation in view of M. abscessus spp. culture-potivity. Subsequently, the patient was treated with nebulized interferon gamma but was again turned down for transplantation due to extensive pleural disease. In June 2011, she had advanced cystic fibrosis requiring ambulatory oxygen and was taking ethambutol, rifampicin, clarithromycin, moxifloxacin, cotrimoxazole and nebulised colistin. Amoxicillin/clavulanic acid, cefepime, ciprofloxacin, doxycycline, minocycline, moxifloxacin, tobramycin and trimethoprim/sulphamethoxazole demonstrated no activity against any of the isolates tested (data not shown). All isolates were found to be resistant to clarithromycin with MICs of >16 μg/ml after 14 days of incubation and 5 out of 6 isolates were resistant to clarithromycin with an MIC of 8 μg/ml from day 5 (Table S1 in File S1). M. bolletii encodes the erythromycin ribosome methyltransferase (erm) determinant which facilitates inducible resistance to clarithromycin [35]. The observed resistance from as early as day 5 of reading susceptibility results is consistent with Patient 1 having received clarithromycin since 2005, with intermittent macrolide treatment prior to that. The isolates tested demonstrated intermediate resistance to amikacin and were fully resistant to cefoxitin and ciprofloxacin. Of note, this patient received treatment with amikacin prior to 2005, which might explain the reduced sensitivity to this antibiotic. All 3 M. abscessus spp. type strains demonstrated sensitivity to amikacin (data not shown). A previous study reported that all M. bolletii isolates exhibited high drug resistance to ciprofloxacin and cefoxitin with intermediate resistance or resistance to amikacin [36]. However M. bolletii isolates susceptible to amikacin and with intermediate resistance to cefoxitin have also been reported in the literature [35]. Taken together, these data demonstrate the high levels of innate in vitro antibiotic resistance among M. bolletii clinical isolates.
Genome-wide Examination of M. bolletii Adaptation to the Human CF Lung

To investigate the molecular adaptation of M. abscessus spp. to the human lung, we determined the whole genome sequence of 6 sequential isolates of M. bolletii obtained over a 12 year period from a single persistently infected patient (Table 2). Isolates were selected to represent the temporal and phenotypic diversity of the isolates obtained from patient 1 (Table 2). The core genome of the 6 strains, identified as all shared nucleotide sites, was comprised of 4,178,261 sites, and we identified 14,594 variable sites with respect to the reference genome of M. bolletii type strain CIP108541 [25]. A total number of 34 SNPs (median coverage 21 reads) and 5 nucleotide insertions or deletions were identified as variable within the core genome among the 6 sequenced genomes (Table 3). A neighbor-joining tree based on the SNP differences identified among the 6 isolates consisted of 3 clades with the 2 isolates obtained in 1999 represented on the same branch (Fig. 3). However, isolates from different years were more closely related to each other than to isolates obtained in the same year indicating the existence of a heterogeneous infecting population containing multiple persisting sub-lineages (Fig. 3). The diversification of bacterial pathogens in the CF lung leading to heterogeneous infecting populations has been previously described for Burkholderia dolosa, Acinetobacter baumannii, and Staphylococcus aureus [12,37,38].

Of the 34 SNPs identified among the 6 isolates, 24 gave rise to non-synonymous mutations (Table 3). Of note, the phoR gene was affected by 2 distinct non-synonymous mutations in 3 out of the 6 isolates (Table 3; Table S3 in File S2). In Mycobacterium tuberculosis PhoR is the histidine kinase component of the two-component system PhoPR involved in the biosynthesis of complex lipids required for growth of M. tuberculosis inside macrophages and mice [39]. The occurrence of multiple independent mutations of phoR implies that phoR attenuation may confer a selective advantage in the CF lung. In the ED1-4R isolate, a large deletion of the mmpL gene which encodes MmpL, a putative membrane protein, was identified. Deletion of mmpLAb has been demonstrated to result in a switch from smooth to rough phenotype [40,41] suggesting that this deletion may be responsible for the rough phenotype of the isolate. Furthermore, several non-synonymous mutations were found in genes that are involved in bacterial metabolism, and regulation of gene expression, leading us to speculate that they may contribute to the radical transition from a saprophytic to human pathogenic lifestyle. Finally, the acquisition of amikacin resistance by M. bolletii relative to the amikacin-sensitive reference strain led us to examine the genome sequence for the underlying mutations responsible. Previous studies have demonstrated that polymorphisms in the 16S rRNA of M. tuberculosis result in resistance to amikacin [42]. However, there were no polymorphisms identified in the 16S rRNA of the amikacin-resistant M. bolletii isolates, suggesting that an alternative mechanism of amikacin resistance may exist in M. bolletii.

Concluding Comments

M. abscessus spp. have emerged as an important cause of pulmonary infection among CF patients with the capacity for long-term persistence leading to clinical deterioration over time. Our genetic typing analysis demonstrates the capacity of M. abscessus spp. isolates to persist for at least 12 years during long-term infection but also indicates that replacement of M. abscessus spp. can occur occasionally during long-term infection. The study provides an indication of the relative prevalence of the 3 M. abscessus species among a selection of infected patients in Scotland and reveals that a single globally distributed ST of M. massilense (ST23) is also prevalent among Scottish patients. An investigation into the origin and pathogenic capacity of ST23 is warranted to understand the basis for the existence of a widespread M. massilense clone among infected patients. Finally, the first genome-wide analysis of the evolution of M. abscessus during long term infection revealed the heterogeneous nature of the infective M. bolletii population, and led to the identification of mutations which may contribute to the adaptation from saprophytic organism to human pathogen. Characterization of the genetic determinants involved in the transition of M. abscessus spp. from initial colonization to severe lung pathology could lead to the identification of novel drug targets for the control of M. abscessus spp. infections.

Supporting Information

File S1 This supporting file includes Figure S1 and Table S1. Figure S1: Phylogenetic analysis of M. abscessus spp. isolates based on single MLST loci. Table S1: Clarithromycin, Cefoxitin and Amikacin MICs determined for isolates from Patient 1.

(File S1: PDF)

File S2 This supporting file includes Table S2 and Table S3. Table S2: Genetic and phenotypic characteristics of each of the 178 study isolates. Table S3: Genome variation among sequential M. bolletii isolates from a single patient.

(XLS)

Acknowledgments

The authors are grateful to Ark Genomics, The Roslin Institute for whole genome sequencing. We thank referring laboratories, Scottish Mycobacterium Reference Laboratory colleagues and clinicians from hospitals in Scotland for discussions and clinical information relating to the patients reported in this article.

Author Contributions

Conceived and designed the experiments: JRF IL. Performed the experiments: KK PM. Analyzed the data: JRF KK PM IL. Contributed reagents/materials/analysis tools: PC ALS AH. Wrote the paper: KK PM IL JRF.

References

1. Aitken ML, Limaye A, Pottinger P, Whimbey E, Goss CH, et al. (2012) Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. American Journal of Respiratory and Critical Care Medicine 185: 231–232.

2. Esther CR, Rockman DA, Gilligan P, Kerr A, Noone PG (2010) Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society 9: 117–123.

3. Viana-Niero C, Lima KVB, Lopes ML, Rabello MC da S, Marsola LR, et al. (2008) Molecular characterization of Mycobacterium massiliense and Mycobacterium bolletii in isolates collected from outbreaks of infections after laparoscopic surgery and cosmetic procedures. Journal of clinical microbiology 46: 850–855.

4. Galli K, Miller LA, Yakrus MA, Wallace RJ, Mosley DG, et al. (1999) Abscesses due to Mycobacterium abscessus linked to injection of unapproved alternative medication. Emerging infectious diseases 5: 681–687.

5. Olivier KN, Weber DJ, Wallace RJ, Faiz AR, Lee J-H, et al. (2003) Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. American journal of respiratory and critical care medicine 167: 828–834.

6. Jonsson BE, Gilljam M, Lindblad A, Ridell M, Wold AE, et al. (2007) Molecular epidemiology of Mycobacterium abscessus, with focus on cystic fibrosis. Journal of clinical microbiology 45: 1497–1504.

7. Bastian S, Veziris N, Roux A-L, Brossier F, Gaillard J-L, et al. (2011) Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrobial agents and chemotherapy 55: 775–781.
8. Macheras E, Roux A-L, Ripoll F, Scavoni-Tardy V, Gutierrez C, et al. (2009) Inaccuracy of single-target sequencing for discriminating species of the Mycobacterium abscessus group. Journal of clinical microbiology 47: 2596–2600.
9. Macheras E, Roux A-L, Bastian S, Leão SC, Palhei M, et al. (2011) Multilocus sequence analysis and rpoB sequencing of Mycobacterium abscessus (sensu lato) strains. Journal of clinical microbiology 49: 491–499.
10. Ciganà C, Curcuru’ L, Leone MR, Ierano` T, Lore` NI, et al. (2009) Pseudomonas aeruginosa exploits lipid A and muramopentapeptide modification as a strategy to lower innate immunity during cystic fibrosis lung infection. PLoS one 4: e4834.
11. Haussler S, Tümmler B, Weisbroth H, Rohde M, Steinmetz I (1999) Small-colony variants of Pseudomonas aeruginosa in cystic fibrosis. Clinical infectious diseases; an official publication of the Infectious Diseases Society of America 29: 621–625.
12. McAdam PR, Holmes A, Templeton KE, Fitzgerald JR (2011) Adaptive Evolution of Staphylococcus aureus during Chronic Endobronchial Infection of a Cystic Fibrosis Patient. PLoS ONE 6: e24301.
13. Kuo Y-M, Cheng A, Wu P-C, Hsieh S-G, Hsieh S-M, et al. (2011) Disseminated Mycobacterium abscessus infection and showerheads, Taiwan. Emerging infectious diseases 17: 2077–2078.
14. Falkingham JO, Norton CD, LeChevallier MW (2001) Factors influencing numbers of Mycobacterium avium, Mycobacterium intracellulare, and other Mycobacteria in drinking water distribution systems. Applied and environmental microbiology 67: 1225–1231.
15. Nesser R, Camhan E, Reyrat JM, Murray A, Gioquil B (2012) Mycobacterium abscessus: a new antibiotic nightmare. The Journal of antimicrobial chemotherapy 67: 810–818.
16. Maurer FP, Rieger G, Ritter C, Bloemberg G V, Bottger EC (2012) Acquisition of clarithromycin resistance mutations in the 23S rRNA gene of Mycobacterium abscessus in the presence of inducible erm(41). The Journal of antimicrobial chemotherapy 67: 2606–2611.
17. Sanguinetti M, Arding F, Fiscarelli E, La Sorda M, D’Argenio P, et al. (2001) Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a patient with cystic fibrosis. Journal of clinical microbiology 39: 816–819.
18. Catherinot E, Roux A-L, Macheras E, Hubert D, Matmat M, et al. (2009) Acute respiratory failure involving an R variant of Mycobacterium abscessus. Journal of clinical microbiology 47: 271–274.
19. Harris KA, Kenna DTD, Blauwendraat C, Hartley JC, Turton JF, et al. (2012) Evaluation of genetic mutations associated with Mycobacterium abscessus infection in cystic fibrosis. Journal of clinical microbiology 50: 1758–1761.
20. Van Soolingen D, Hermans PW, De Haan PE, Soll DR, Van Embden JD (1991) Occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. Journal of clinical microbiology 29: 2576–2580.
21. Sampaio JLM, Viana-Niero C, De Freitas D, Holling-Lima AL, Leão SC (2006) Enterobacterial repetitive intergenic consensus PCR is a useful tool for typing Mycobacterium chelonae and Mycobacterium abscessus isolates. Diagnostic microbiology and infectious disease 55: 107–110.
22. Leão SC, Zanetti S, Duper I, Delougo G, Fadda G (1998) Enterobacterial repetitive intergenic consensus sequences as molecular targets for typing of Mycobacterium tuberculosis. Journal of clinical microbiology 36: 128–132.
23. Kerse M, Moir R, Wilson A, Stones-Havas S, Cherung M, et al. (2012) GenoType Basic: An integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics (Oxford, England) 28: 1647–1649.
24. Gordon A (2010) FASTX-toolkit. Available: http://hannonlab.cshl.edu/fastx-toolkit/index.html. Accessed 2013 Apr 11.
25. Choi G-E, Cho Y-J, Koh W-J, Chun J, Cho S-N, et al. (2012) Draft genome sequence of Mycobacterium abscessus subsp. bolletii BD(T). Journal of bacteriology 194: 2756–2757.
26. Li H, Durbin R (2009) Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25: 1754–1760.
27. Bange FC, Brown BA, Smaczny C, Wallace Jr RJ, Bottger EC (2001) Lack of transmission of Mycobacterium abscessus among patients with cystic fibrosis attending a single clinic. Clinical infectious diseases; an official publication of the Infectious Diseases Society of America 32: 1648–1650.
28. Cullen AR, Cannon CL, Mark EJ, Collin AA (2000) Mycobacterium abscessus infection in cystic fibrosis. Colonization or infection? American journal of respiratory and critical care medicine 161: 641–645.
29. Kim H-Y, Kook Y, Yun Y-J, Park GG, Lee NY, et al. (2008) Proportions of Mycobacterium massiliense and Mycobacterium abscessus group isolates. Journal of clinical microbiology 46: 3304–3309.
30. Zelazny AM, Root JM, Shek YR, Colombo RE, Shampeta IC, et al. (2009) Cohort study of molecular identification and typing of Mycobacterium abscessus, Mycobacterium massiliense, and Mycobacterium bolletii. Journal of clinical microbiology 47: 1985–1995.
31. Maloney S, Welbel S, Davies B, Adams K, Becker S, et al. (1994) Mycobacterium abscessus pseudo-infection traced to an automated endoscope washer: utility of epidemiologic and laboratory investigation. The Journal of infectious diseases 160: 1166–1169.
32. Fraser VJ, Jones M, Murray PR, Medoff G, Zhang Y, et al. (1992) Contamination of flexible fiberoptic bronchoscopes with Mycobacterium chelonae linked to an automated bronchoscope disinfection machine. The American review of respiratory disease 145: 853–855.
33. Huang W-C, Chiou C-S, Chen J-H, Shen G-H (2010) Molecular epidemiology of Mycobacterium abscessus infections in a subtropical chronic ventilatory setting. Journal of medical microbiology 59: 1203–1211.
34. Catherinot E, Clarissou J, Etienne G, Ripoll F, Emile J-F, et al. (2007) Hypervirulence of a rough variant of the Mycobacterium abscessus type strain. Infection and immunity 75: 1055–1058.
35. Nash KA, Brown-Elliott BA, Wallace RJ (2009) A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrobial agents and chemotherapy 53: 1371–1376.
36. Adembai T, Drancourt M (2009) Mycobacterium bolletii respiratory infections. Emerging infectious diseases 15: 302–305.
37. Silbert S, Barth AL, Sader HS (2001) Heterogeneity of Pseudomonas aeruginosa in Brazilian cystic fibrosis patients. Journal of clinical microbiology 39: 3976–3981.
38. Lieberman TD, Michel JB, Aingaran M, Potter-Bynoe G, Rousse D, et al. (2011) Parallel bacterial evolution within multiple patients identifies candidate pathogenicity genes. Nature genetics 43: 1275–1280.
39. Walters SB, Dubnaeu E, Kolesnikova I, Laval F, Daffe M, et al. (2006) The Mycobacterium tuberculosis PhePR two-component system regulates genes essential for virulence and complex lipid biosynthesis. Molecular microbiology 60: 312–330.
40. Medjahed H, Reyrat JM (2009) Construction of Mycobacterium abscessus defined glycopeptidolipid mutants: comparison of genetic tools. Applied and environmental microbiology 75: 1331–1338.
41. Nesser R, Reyrat JM, Davidson LB, Byrd TF (2011) Deletion of the mmpL4b gene in the Mycobacterium abscessus glycopeptidolipid biosynthetic pathway results in loss of surface colonization capability, but enhanced ability to replicate in human macrophages and stimulate their innate immune response. Microbiology (Reading, England) 157: 1187–1195.
42. Georgiouso SB, Magana M, Garfin RS, Catanzaro DG, Catanzaro A, et al. (2012) Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PloS one 7: e33275.